GigXR, Inc., a leading provider of holographic healthcare training, has announced a collaboration with the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine). This partnership aims to introduce a new gastrointestinal module for the HoloScenarios application, designed to enhance the training of medical and nursing students in diagnosing and treating acute gastrointestinal diseases. The HoloScenarios: Gastrointestinal module offers evidence-based clinical simulations featuring hyperrealistic holographic simulated patients and medical equipment, accessible from anywhere globally. Key Highlights:
Author: Abhay Panchal
In 2023, prior authorization has emerged as a significant concern in the field of gastroenterology. Dr. Benjamin Levy III, a gastroenterologist at the University of Chicago Medicine, discussed the challenges posed by prior authorizations in an interview with Becker’s. He highlighted several key points: In summary, while prior authorizations aim to ensure appropriate care, they also introduce administrative challenges that can hinder timely patient care and increase costs.
Artificial intelligence (AI) already is making a difference in healthcare by helping medical professionals interpret tests, clarify diagnoses and identify the most effective treatment approaches to a range of diseases. As Cedars-Sinai explores new uses of AI, it is balancing the rapid development of this emerging technology with responsible and ethical implementation. “AI systems have the power to transform healthcare,” said Mike Thompson, vice president of Enterprise Data Intelligence at Cedars-Sinai. “If implemented properly and responsibly, AI can be deployed to enhance patient experience, improve population health, reduce costs and improve the work life of healthcare providers.” Thompson sat down…
A next-generation, multitarget stool DNA test, known as the next-generation Cologuard, has demonstrated a 94% sensitivity and 91% specificity in detecting colorectal cancer, surpassing the performance of fecal immunochemical testing (FIT). Thomas F. Imperiale, MD, from Indiana University Medical Center, highlighted that this version of Cologuard differs from FIT due to its unique markers, which are all methylated DNA markers. In the BLUE-C study, which involved 26,758 participants, the next-generation Cologuard showed a higher likelihood of detecting cancer (94% vs. 67%) and precancerous lesions (43% vs. 23%) compared to FIT. Imperiale emphasized the significance of the improved specificity, which is…
Motus GI Holdings, Inc., a medical technology company focused on enhancing endoscopic outcomes, has announced that it has secured clearance from the U.S. Food and Drug Administration (FDA) for its new Pure-Vu EVS Gastro and Gen 4 Colon system. This clearance paves the way for the company to tap into the upper gastrointestinal (GI) market, addressing the needs of patients with upper GI bleeds, a condition with high mortality rates. The new Pure-Vu systems offer significant improvements over previous models, aiming to provide better visualization in both the upper and lower GI tracts. These advancements include a more powerful suction…
Microsoft and Google have recently introduced new features for their healthcare cloud products, aiming to consolidate data from diverse sources such as EHRs, labs, revenue cycles, and more. This integration will enable healthcare organizations to derive insights from various datasets or establish standardized processes. Key Points:
American patients are divided regarding their comfort with the application of artificial intelligence (AI) in their healthcare experiences. A survey conducted by Propeller Insights on behalf of Carta Healthcare revealed the following:
The gastroenterology industry is witnessing rapid advancements with the integration of artificial intelligence and innovative technologies, offering specialists novel methods to care for and treat patients. Here are five groundbreaking GI-industry devices:
An app-based digital therapeutic has shown significant efficacy in reducing symptoms and enhancing the quality of life, work productivity, and health literacy among patients with irritable bowel syndrome (IBS). These findings are from the ColoFuture Study, presented at the UEG Week 2023. Key Findings:
In this month’s column, I highlight three topics that are highly relevant to endoscopy clinical practice: colon polyp sizing, Helicobacter pylori’s relationship with gastric cancer and large nonpedunculated polyps. Although pathologists report the size of colon polyps resected during colonoscopy, the accuracy of such size reporting is questionable. In this study, investigators showed that due to factors such as piecemeal resection, only 60% of polyps sent to pathology can be measured, and of those that are measured, shrinkage of polyp size occurs in almost 25% of the specimens. The majority of the results showing a reduction in gastric incidents after…